Vanguard Group Inc Akebia Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKBA
# of Institutions
189Shares Held
121MCall Options Held
267KPut Options Held
280K-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
-
Morgan Stanley New York, NY4.32MShares$7.34 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...